Sarah Rhead
Overview
Explore the profile of Sarah Rhead including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
4675
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koen A, Izu A, Baillie V, Kwatra G, Cutland C, Fairlie L, et al.
Vaccine
. 2023 May;
41(23):3486-3492.
PMID: 37149443
COVID-19 vaccine efficacy (VE) has been observed to vary against antigenically distinct SARS-CoV-2 variants of concern (VoC). Here we report the final analysis of VE and safety from COV005: a...
2.
Madhi S, Kwatra G, Richardson S, Koen A, Baillie V, Cutland C, et al.
Lancet Infect Dis
. 2022 Oct;
23(3):295-306.
PMID: 36273491
Background: COVID-19 vaccine rollout is lagging in Africa, where there has been a high rate of SARS-CoV-2 infection. We aimed to evaluate the effect of SARS-CoV-2 infection before vaccination with...
3.
Li G, Cappuccini F, Marchevsky N, Aley P, Aley R, Anslow R, et al.
Lancet
. 2022 Jun;
399(10342):2212-2225.
PMID: 35691324
Background: Vaccination of children and young people against SARS-CoV-2 is recommended in some countries. Scarce data have been published on immune responses induced by COVID-19 vaccines in people younger than...
4.
Ogbe A, Pace M, Bittaye M, Tipoe T, Adele S, Alagaratnam J, et al.
JCI Insight
. 2022 Feb;
7(7).
PMID: 35192543
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male...
5.
Madhi S, Koen A, Izu A, Fairlie L, Cutland C, Baillie V, et al.
Lancet HIV
. 2021 Aug;
8(9):e568-e580.
PMID: 34416193
Background: People living with HIV are at an increased risk of fatal outcome when admitted to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to assess safety and...
6.
Frater J, Ewer K, Ogbe A, Pace M, Adele S, Adland E, et al.
Lancet HIV
. 2021 Jun;
8(8):e474-e485.
PMID: 34153264
Background: Data on vaccine immunogenicity against SARS-CoV-2 are needed for the 40 million people globally living with HIV who might have less functional immunity and more associated comorbidities than the...
7.
Madhi S, Baillie V, Cutland C, Voysey M, Koen A, Fairlie L, et al.
N Engl J Med
. 2021 Mar;
384(20):1885-1898.
PMID: 33725432
Background: Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of...
8.
Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P, et al.
Lancet
. 2020 Dec;
397(10269):99-111.
PMID: 33306989
Background: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated...
9.
Ramasamy M, Minassian A, Ewer K, Flaxman A, Folegatti P, Owens D, et al.
Lancet
. 2020 Nov;
396(10267):1979-1993.
PMID: 33220855
Background: Older adults (aged ≥70 years) are at increased risk of severe disease and death if they develop COVID-19 and are therefore a priority for immunisation should an efficacious vaccine...